NIH Scientists Find Weak Points on Epstein-Barr Virus

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

BIO names John Crowley as new CEO

The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the biotech industry, to fill the role of the organization’s new CEO.